Drug Development

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

Complex formulations, personalized medicines, COVID-19 therapies, and sustainability goals are driving innovations in drug packaging.

Injecting Innovation into Drug Packaging

Vaccine development is inherently challenging; however, in light of the COVID-19 pandemic, innovations have been prioritized, leading to accelerated development processes.

Overcoming Vaccine Development Challenges

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Aprecia and Glatt investigate manufacturing technologies to widen the formulation design space for oral delivery.

Combining Multiparticulates and 3DP for Patient-Centric Dosage Forms

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Mass spectrometry and automation are growing in importance for protein characterization, but further improvements are still needed.

Evolving Analytical Technology Unravels Protein Characteristics

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Updates to user fee programs that fund FDA operations are being finalized by industry stakeholders for approval by Congress.

FDA and Industry Move to Renew New Drug User Fee Programs

The European Medicines Agency and the European Centre for Disease Prevention  have joined forces in a new initiative aimed at strengthening the post-marketing surveillance of COVID-19 vaccines in Europe.

EMA, ECDC Team Up to Strengthen Post-Marketing Surveillance of COVID-19 Vaccines

Moderna’s investments will double the formulation fill/finish and drug substance manufacturing of its vaccine to up to three billion doses in 2022 at various manufacturing sites. 

Moderna Announces Additional Investments to Increase COVID-19 Vaccine Supply for 2022

With a $5 million grant from DARPA, DNA Script and Moderna will develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the DARPA’s Nucleic Acids On-Demand World-Wide program.

DNA Script to Team up With Moderna for Vaccine and Therapeutic Manufacturing for DARPA

Sanofi will perform the fill/finish of up to 200 million doses of Moderna’s COVID-19 vaccine at its Ridgefield, NJ, facility starting in September 2021. 

Sanofi to Manufacture up to 200 Million Doses of Moderna’s COVID-19 Vaccine

The decision comes from the US CDC Advisory Committee on Immunization Practices following the evaluation of data showing a rare adverse event involving blood clots in combination with low platelet counts within approximately one to two weeks following vaccination.

Formulation and Drug Delivery